TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from CapsoVision, Inc. ( (CV) ) is now available.
On July 1, 2025, CapsoVision, Inc. announced the pricing of its initial public offering, selling 5,500,000 shares of common stock at $5.00 per share, raising approximately $27.5 million in gross proceeds. The shares began trading on the Nasdaq Capital Market under the symbol ‘CV’ on July 2, 2025, and the offering closed on July 3, 2025. The company granted underwriters a 30-day option to purchase an additional 825,000 shares, and issued warrants to Benchmark and Roth for 165,000 shares. The proceeds will support CapsoVision’s operations and growth in the medical technology sector.
More about CapsoVision, Inc.
CapsoVision, Inc. is a commercial-stage medical technology company that specializes in developing advanced imaging and AI-enabled solutions for gastrointestinal disease detection and diagnosis. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope designed for high-resolution visualization of the small bowel. The company is also working on CapsoCam Colon, aimed at non-invasive colon imaging and polyp detection, with a platform expanding to multiple GI indications.
For an in-depth examination of CV stock, go to TipRanks’ Overview page.